Takara Bio | GenomeWeb

Takara Bio

The deal is expected to help Takara Bio Group expand its presence in next-generation sequencing library preparation and other markets.

The deal is expected to broaden Takara's portfolio of products for next-generation sequencing library preparation and genetic analysis.

The company recently urged shareholders to approve the deal, saying the cash consideration they'd receive would represent a premium over recent stock prices.

The institute has selected the firm's RNA-seq library preparation kits for use in gene expression profiling in single-cell analysis of brain cells.

The single-cell analysis firm told shareholders that while the final offer from Takara is not set in stone, they're unlikely to be offered better terms.

Last month, the companies announced that Takara Bio USA — formerly Clontech Laboratories and now a subsidiary of Japan's Takara Bio — would acquire WaferGen.

Takara said it will pay an aggregate cash purchase price that will be based on a multiple of WaferGen's 2016 revenues, capped at $50 million.

The companies will combine their respective technologies and expertise to develop new products for low-input, targeted RNA-seq applications.

The method was developed in the laboratory of Rickard Sandberg at the Ludwig Institute for Cancer Research in Stockholm and published by his group in 2013.

NEW YORK (GenomeWeb News) — Genedata announced today that Takara Bio has chosen the Genedata Expressionist software platform for use in all its genomics, transcriptomics, and epigenomics research.

Pages

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.